TY - JOUR
T1 - Digital Breast Tomosynthesis (DBT) to Characterize MRI-Detected Additional Lesions Unidentified at Targeted Ultrasound in Newly Diagnosed Breast Cancer Patients
AU - Mariscotti, Giovanna
AU - Houssami, Nehmat
AU - Durando, Manuela
AU - Campanino, Pier Paolo
AU - Regini, Elisa
AU - Fornari, Alberto
AU - Bussone, Riccardo
AU - Castellano, Isabella
AU - Sapino, Anna
AU - Fonio, Paolo
AU - Gandini, Giovanni
PY - 2015/9/10
Y1 - 2015/9/10
N2 - Objectives: Preoperative breast magnetic resonance (MR) often generates additional suspicious findings needing further investigations. Targeted breast ultrasound (US) is the standard tool to characterize MR additional lesions. The purpose of this study is to evaluate the potential role of digital breast tomosynthesis (DBT) to characterize MR detected additional findings, unidentified at targeted breast US. Methods: This prospective study included women who a) had biopsy-proven, newly diagnosed breast cancers detected at conventional 2D mammography and/or US, referred to breast MR for tumour staging; and b) had DBT if additional MR findings were not detected at targeted (‘second look’) US. Results: In 520 patients, MR identified 164 (in 114 women, 22 %) additional enhancing lesions. Targeted US identified 114/164 (69.5 %) of these, whereas 50/164 (30.5 %) remained unidentified. DBT identified 32/50 of these cases, increasing the overall characterization of MR detected additional findings to 89.0 % (146/164). Using DBT the identified lesions were significantly more likely to be malignant than benign MR-detected additional lesions (p = 0.04). Conclusions: DBT improves the characterization of additional MR findings not identified at targeted breast US in preoperative breast cancer staging. Key points: • Targeted US identified 114 of 164 (69.5 %) additional enhancing lesions at preoperative breast MRI. • DBT identified a further 32 of the 50 lesions unidentified on targeted US. • DBT improved the characterization of additional MR findings for breast cancer staging.
AB - Objectives: Preoperative breast magnetic resonance (MR) often generates additional suspicious findings needing further investigations. Targeted breast ultrasound (US) is the standard tool to characterize MR additional lesions. The purpose of this study is to evaluate the potential role of digital breast tomosynthesis (DBT) to characterize MR detected additional findings, unidentified at targeted breast US. Methods: This prospective study included women who a) had biopsy-proven, newly diagnosed breast cancers detected at conventional 2D mammography and/or US, referred to breast MR for tumour staging; and b) had DBT if additional MR findings were not detected at targeted (‘second look’) US. Results: In 520 patients, MR identified 164 (in 114 women, 22 %) additional enhancing lesions. Targeted US identified 114/164 (69.5 %) of these, whereas 50/164 (30.5 %) remained unidentified. DBT identified 32/50 of these cases, increasing the overall characterization of MR detected additional findings to 89.0 % (146/164). Using DBT the identified lesions were significantly more likely to be malignant than benign MR-detected additional lesions (p = 0.04). Conclusions: DBT improves the characterization of additional MR findings not identified at targeted breast US in preoperative breast cancer staging. Key points: • Targeted US identified 114 of 164 (69.5 %) additional enhancing lesions at preoperative breast MRI. • DBT identified a further 32 of the 50 lesions unidentified on targeted US. • DBT improved the characterization of additional MR findings for breast cancer staging.
KW - Breast cancer
KW - Cancer staging
KW - Magnetic resonance imaging
KW - Tomosynthesis
KW - Ultrasound
UR - http://www.scopus.com/inward/record.url?scp=84938962367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938962367&partnerID=8YFLogxK
U2 - 10.1007/s00330-015-3669-4
DO - 10.1007/s00330-015-3669-4
M3 - Article
C2 - 25813013
AN - SCOPUS:84938962367
VL - 25
SP - 2673
EP - 2681
JO - European Radiology
JF - European Radiology
SN - 0938-7994
IS - 9
ER -